9/12 5:30 pm - 8:30 pm
HBA presents 'Putting Academia-Industry Research Partnerships to Work.' Novartis, 1 Health Plaza, East Hanover, NJ more
9/24 4:00 pm - 6:00 pm
CURE presents healthcare investment banker Anthony Gibney of Leerink Swann. Yale Anlyan Center, 300 Cedar Street, New Haven more
10/1 4:00 pm - 6:00 pm
CURE/Yale BioHaven presents Trevi Therapeutics. Anlyan Center, 300 Cedar Street, New Haven. Watch for details.
10/8-9 12th annual BIO Investor Forum. The Palace Hotel, San Francisco more
10/15 6:00 pm - 9:30 pm
HBA presents Women's Healthcare Innovation and Leadership Showcase. Sanofi Campus, 55 Corporate Drive Auditorium, Bridgewater, NJ more
11/7 10:00 am - 3:00 pm
CT Innovation Summit. Mentor meetings, awards ceremony, and more. Co-sponsored by CURE. Oakdale Theater, Wallingford more
11/11-13 The BIO Convention in China. National Convention Center, Beijing more
12/3 5:45 pm - 7:30 pm
CURE Holiday Party. 'The best networking in town.' Café George, 300 George Street, New Haven. Save the Date!

Cost-saving discounts for CURE members!
CURE members can now receive discounts on various products and services, such as lab supplies, shipping services, and gases more


Achillion Pharmaceuticals, Inc.
300 George Street
New Haven, CT 06511

Phone: 203-624-7000
Fax: 203-624-7003
Website: http://www.achillion.com

Contact(s)
info@achillion.com

General Information
Achillion is an innovative pharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. The company's proven discovery and development teams have advanced multiple product candidates, including several with novel mechanisms of action. Achillion is focused on solutions for the most challenging problems in infections disease - HIV, hepatitis and resistant bacterial infections. Our drug candidates tend to be small molecules directed at the $40 billion worldwide infectious disease market. Achillion's lead product candidate is elvucitabine for use in patients chronically infected with HIV, which has demonstrated potent anti-HIV activity, as well as an exceptionally long half-life, a feature that may stem the emergence of drug resistance.

Research Activities
Achillion's powerful drug discovery engine embodies both a conventional medicinal chemistry approach directed at classical anti-infective molecular targets and its novel chemistry approach directed at classical anit-infective molecular targets and its novel Zinc Finger Targeting (ZFT) drug discovery technology focusing on novel proteins containing zinc finger motifs. ZFT has broad applicability against a variety of organisms an cell types: viruses, fungi, parasites, bacteria and cancer. Using ZFT technology, Achillion selectively targets diverse pathogens to apply its medicinal chemistry and drug development expertise to develop breakthrough products to treat serious infectious diseases with unmet medical needs.

Other Information
Ownership: Private
CT Employees: 40
World Employees: 40

Back